Since our study shows that Cfs are DNA damaging agents with implications for diverse diseases associated with elevated Cfs levels, removal of Cfs could be of therapeutic value. We have developed pullulan-based histone antibody nanoconjugates for the removal of Cfs from circulation. Nanoconjugates were developed and various physico-chemical characterizations were carried out. The efficacy of these nanoconjugates on removing Cfs was evaluated both in vitro and in vivo. Our results indicate that nanoconjugates may have therapeutic value in reducing inflammation and fatality in a mouse model of sepsis and in preventing neutropenia following treatment with Adriamycin both of which are mediated via Cfs.